Showing posts with label warfarin. Show all posts
Showing posts with label warfarin. Show all posts

Monday, 4 August 2025

Warfarin: Influence of Genetic Variations and Their Prevalence in Indian Population | Chapter 1 | Medicine and Medical Research: New Perspectives Vol. 1

 

Warfarin has been the most trusted but challenging anticoagulant in clinical practice for the last seven decades. The challenge is to manage its dose. A narrow therapeutic index and high inter- and intra-individual variability in drug disposition and response are the factors that shift the pendulum to adverse drug events from one end of fatal hemorrhage to the other i.e. thrombosis. The difficult task for clinical management is to maintain the required international normalized ratio (INR) with warfarin therapy. Factors responsible for this difficult task include both genetic and non-genetic. The predominant genes are those coding for vitamin K epoxide reductase complex (VKORC) subunit 1 (VKORC1; the target of warfarin and the enzyme of warfarin metabolism; cytochrome P450 enzyme 2C9 (CYP2C9). There is general agreement among published retrospective population studies that the combination of VKORC1 and CYP2C9 genotypes, together with gender, age, body mass index or height or weight and concurrent medications, predict approximately 50% of warfarin dose requirement. Thus, genetic testing will be able to predict and help in directing toward the correct dose and reduce the counts of trial and error as well as risks during therapy. Within the Asian population, Indian patients have been reported to require higher warfarin doses than others. Here we also review the prevalence of the genetic variations of VKORC1 and CYP2C9 associated with variable warfarin response in Indian populations from different regions and also depict studies that have aimed at analysing the influence of genotypic variations to the clinical dose of Warfarin in the Indian population.

 

 

Author(s) Details

Kavita Shalia
Sir H. N. Medical Research Society, Sir H. N. Hospital and Research Centre, Court House, L. T. Road, Mumbai 400002, India.

Sunila Raju
Sir H. N. Medical Research Society, Sir H. N. Hospital and Research Centre, Court House, L. T. Road, Mumbai 400002, India.

Amit Chandan
Sir H. N. Reliance Foundation Hospital and Research Centre, Raja Rammohan Roy Road, Mumbai 400004, India.

 

Please see the link:- https://doi.org/10.9734/bpi/mmrnp/v1/1194

Thursday, 13 October 2022

Therapeutic Dilemmas in Acute Ischemic Strokes and Concomitant Cardiac Thromboembolism: Case Series | Chapter 15 | Current Innovations in Medicine and Medical Science Vol. 3

 Ischemic stroke is a leading cause of morbidity and mortality worldwide. Anticoagulation remedy in cases with cerebral ischemic events caused by cardiac emboli is no longer debatable. The issue is deciding when to begin. Because of a rush rate of 15 to 20 in the first many weeks after the original event, direct anticoagulation with intravenous heparin followed by oral anticoagulants appears to be indicated. The ideal of this study is about managing cases with acute ischemic strokes and pitfalls of development of embolic events taking into account the pitfalls of hemorrhagic complications while treating them. We present two cases of cases who had a cardio- embolic stroke due to cardiac thrombosis and were in a remedial double bind about when to begin anticoagulation treatment. Beforehand anticoagulation treatment was associated with favourable clinical and neurological issues.


Author(s) Details:

Rajish Sanjit Kumar Shil,
Health Education England, Liverpool, United Kingdom.

Mohamed Salah Gamea,
Department of Neurology, Madinat Zayed Hospital, Abu Dhabi, United Arab Emirates.

Noor Ullah Hussaini Mohammed,
Department of Neurology, Madinat Zayed Hospital, Abu Dhabi, United Arab Emirates.

Renganathan Radhakrishnan,
Czech Rehabilitation Hospital, Al Ain, United Arab Emirates.

Please see the link here: https://stm.bookpi.org/CIMMS-V3/article/view/8389